Pertussis Vaccines: Whole-cell & Acellular Vaccines, Different Types & Manufacturers along with the Regimen in Various Age Groups

Infectious Diseases

The Mesh of the Generics and the Potential of E...

Smoking is the leading preventable cause of death in the world. However, prior to 1900, tobacco smoking was an uncommon sight. It was not until the 20th century that smoking cigarettes became a rou...

Feb 05, 2021

recent-pharma-biotech-happenings-for-bms-prothena-canon-medical-immunovant
Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs

Plaque psoriasis drug outshines the competition in phase III trial Bristol Myers Squibb’s psoriasis drug, the TYK2 inhibitor outshone placebo and Amgen’s Otezla in a second phase 3 study, setting discussions with regulators. The study, known as POETYK PSO-2, trialled the drug, deucravacitinib, against placebo...

Find More
fake-news-misinformation-in-the-healthcare-medical-health-sector
Fake News In The Healthcare Sector: A Misinformation Crisis In The Era Of Digitalization

Information and Communications Technology (ICT) over the past few years have changed the way of communication. Among all the communication mediums, social media, in particular, has got a lot of attention and offers a huge benefit over traditional media. It has empowered the common man to quickly and easily get acce...

Find More
Horizon, Viela Deal; Concert Schizophrenia Drug Flop; Gilead, Gritstone Deal
Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone

Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the...

Find More

More Views & Analysis

Aurinia's Lupkynis for Lupus; Toripalimab; Merck’s Covid-19 Vaccines fail
Aurinia’s Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Wren Therapeutics’ Financing; Merck’s Covid-19 Vaccine Program End

Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...

Find More

Thrombocytopenia drugs market | Drug-Induced Thrombocytopenia
Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market?

The launch of a novel drug in the market is not less than a celebration in the pharmaceutical and healthcare market; however, it also brings the real challenge of sustenance in the market. Similar is the picture of the Thrombocytopenia Drugs Market. Thrombocytopenia pipeline possesses potential drugs in mid-stage d...

Find More

recent-pharma-news-and-updates
Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off

Medivir, IGM Biosciences enters into an exclusive licensing agreement for Birinapant Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. Birinapant is a clinical-stage SMAC mimetic that degrades Inhibitors of Apoptosis ...

Find More

Hepatitis D Market | Hepatitis D Treatment Market | HDV Market
Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook?

Recent years have been experiencing a dramatic increase in the number of Hepatitis D cases. It is spreading at a rapid rate. DelveInsight estimated that the total diagnosed Hepatitis D prevalence was reported to be 204,976 in 2017 in the 7MM (the US, EU5 (the UK, Germany, Spain, France, and Italy) and Japan). Furth...

Find More

recent-pharma-biotech-news-updates-for-ikena-terns-ribometrix-hologic
Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics

Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The Series B round begins as Ikena prepares to add a TEAD inhibitor to its roster of clinical programs and pushes a first-in-class KRAS asset th...

Find More

Chronic Hepatitis B Market
Search for the Cure Continues in the Chronic Hepatitis B Treatment Market

Hepatitis B virus (HBV) infection is the 10th leading cause of death worldwide. With 2 billion people infected all over, HBV infection is a reason behind 500 000 to 1.2 million deaths per year. Hepatitis B is a lethal infection and has been a major global problem for years. If it lasts for over 6 months, it is term...

Find More

Alopecia Areata (AA) is an autoimmune disorder that leads to hair loss on the scalp, face, and on ot.....

Find More

Transthyretin Amyloidosis (ATTR) is a progressive build-up of abnormal deposits of amyloid protein i.....

Find More

Ankylosing spondylitis (AS) is an inflammatory disease that results in a progressive fusion of some .....

Find More

Digital health technologies can fill the current gaps in oncology care while rebalancing the existin.....

Find More

Cancer, an immunologic condition that can begin in any organ or tissue of the body is the second lea.....

Find More

RNAi is a fundamental gene-silencing pathway in eukaryotic cells, where long pieces of double-strand.....

Find More